Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
AVLN Catalyst Timeline
Dated clinical, regulatory and corporate events for Avalyn Pharma Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Avalyn Pharma Inc.
Upcoming catalysts 2
Event history 14
Past FDA Catalysts and PDUFA Decisions
How AVLN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Drug Pipeline Intelligence
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AP01 Small MoleculesNCT06329401 | Pulmonary Fibrosis | Phase 2 | ACTIVE NOT_RECRUITING | 398 | Jun 1, 2027 | ||||||
| AP01 Small MoleculesNCT06951217 | Progressive Pulmonary Fibrosis | Phase 2 | RECRUITING | 340 | Dec 31, 2031 | ||||||
| AP02 Small MoleculesNCT07194382 | Idiopathic Pulmonary Fibrosis (IPF) | Phase 2 | RECRUITING | 160 | Jun 1, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every AVLN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| AP01 | progressive pulmonary fibrosis | Phase 2b | 2026-05-06 | encouraging safety and clinical activity across Phase 1b and an ongoing, multi-year open-label extension trial, with long-term data supporting the potential to preserve lung function while improving tolerability relative to historical oral pirfenidoneRead More | Avalyn to Present Patient-Centered Research on AP01 Delivery and Supportive Care Experiences at American Thoracic Society 2026 International ConferenceRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| FMR LLC10% Owner, See Remark 1 | Sell | -5,565 2,103,970 held | $29.56 | 11/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in AVLN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 1.3 % | 76.22 M | 2.68 M |
Ownership Trends
AVLN Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How AVLN ranks across every disease it competes in
AVLN News
Avalyn Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Avalyn Pharma reported its third quarter 2026 financial results, highlighting the initiation of a Phase 1 study for AP03, a combination therapy. The company presented promising data for AP01 and AP02 at the ERS Congress. With $386.6 million in cash, Avalyn is well-positioned to advance its pipeline into 2029.
Read more →Avalyn to Present at Upcoming Investor Conferences
Avalyn Pharma Inc. announced its participation in several upcoming investor conferences, including the Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference. The company is advancing inhaled therapies for serious respiratory diseases, with promising results from its clinical trials for AP01 and AP02 programs. These efforts aim to improve treatment outcomes for pulmonary fibrosis.
Read more →Avalyn Publishes Phase 1 Data Highlighting AP02’s Lung-Targeted Delivery and Encouraging Safety Profile
Avalyn has published Phase 1 data showcasing the effectiveness of AP02 in delivering antifibrotic medicines directly to the lungs. This approach aims to enhance local exposure while minimizing systemic effects, leading to improved tolerability. The findings support further development of AP02 for treating idiopathic pulmonary fibrosis, with ongoing patient enrollment.
Read more →Avalyn Appoints Robert J. Meyer, MD, to its Board of Directors
Avalyn Pharma has appointed Dr. Robert J. Meyer to its Board of Directors. Dr. Meyer, a seasoned pulmonary physician and former FDA leader, brings over 25 years of experience in regulatory and clinical development. His expertise is expected to guide Avalyn's ongoing clinical programs, including AP01 and AP02, aimed at treating serious respiratory diseases. The company is focused on transforming treatment paradigms for pulmonary fibrosis through innovative inhaled therapies.
Read more →Avalyn Presents New Data at ERS Congress 2026 Supporting AP01 Lung Distribution and Patient-Centered Trial Design in Pulmonary Fibrosis
Avalyn Pharma presented new data at the ERS International Congress 2026, highlighting the predicted aerosol distribution of their inhaled therapy AP01 in both healthy and severely fibrotic lungs. The findings emphasize the importance of patient perspectives in clinical trial design, revealing a strong willingness among patients with idiopathic pulmonary fibrosis to participate in research. The data supports the potential for AP01 to deliver effective treatment directly to areas impacted by disease.
Read more →Avalyn to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Avalyn Pharma Inc. will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026. The company focuses on developing inhaled therapies for serious respiratory diseases, including pulmonary fibrosis. Their AP01 and AP02 programs are currently in clinical trials, showcasing promising results in safety and efficacy.
Read more →Avalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026
Avalyn Pharma will present two posters at the European Respiratory Society International Congress 2026 in Barcelona. The presentations cover patient perspectives on clinical trial design and in silico modeling of its AP01 formulation. These sessions highlight the company's focus on integrating patient input and predicting lung distribution for its inhaled therapies. The event takes place from September 5 to 9, 2026.
Read more →Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Avalyn Pharma completed enrollment of its MIST global Phase 2b trial for AP01 with 398 patients. Topline data from this study is expected in the second half of 2027. The company ended the second quarter of 2026 with $413.5 million in cash and marketable securities. This balance is projected to fund operations into 2029.
Read more →Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis
Avalyn Pharma has successfully completed target enrollment of 375 patients for the Phase 2b MIST trial evaluating AP01, an inhaled formulation of pirfenidone for progressive pulmonary fibrosis (PPF). The trial aims to assess the safety and efficacy of AP01 compared to a placebo over 52 weeks. Topline results are anticipated in the second half of 2027, and the company expresses optimism about the potential benefits of AP01 based on previous clinical data.
Read more →Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights
Avalyn Pharma reported its Q1 2026 financial results, highlighting progress in its clinical trials for inhaled therapies targeting pulmonary fibrosis. The company is on track to complete enrollment in the MIST Phase 2b trial of AP01 by mid-2026 and has initiated the AURA Phase 2 trial for AP02. Following a successful IPO, Avalyn has sufficient funds to support its operations through 2029. The company aims to redefine treatment standards for serious respiratory diseases.
Read more →Avalyn to Participate in the Jefferies Global Healthcare Conference
Avalyn Pharma Inc. will present a company overview at the Jefferies Global Healthcare Conference on June 4, 2026. The presentation will highlight Avalyn's innovative inhaled therapies aimed at treating serious respiratory diseases, particularly their ongoing clinical trials for pulmonary fibrosis. The company is focused on transforming treatment paradigms with optimized formulations of established antifibrotic medicines.
Read more →Avalyn Announces Additional Long-term Data on AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis to be Presented at the European Alliance of Associations for Rheumatology 2026
Avalyn Pharma Inc. announced that it will present updated long-term data on AP01, an inhaled formulation of pirfenidone, at the EULAR 2026 conference. The findings from the ATLAS trial will focus on the drug's tolerability in patients with progressive pulmonary fibrosis over four years. This presentation aims to highlight the potential benefits of inhaled therapies for serious respiratory diseases.
Read more →Avalyn to Present Patient-Centered Research on AP01 Delivery and Supportive Care Experiences at American Thoracic Society 2026 International Conference
Avalyn Pharma will present patient-centered research at the ATS 2026 International Conference, focusing on inhaled therapies for pulmonary fibrosis. The presentations include findings from a usability study of the eFlow® Nebulizer System and patient perspectives on supportive healthcare experiences. Avalyn aims to enhance treatment through direct patient input and innovative inhaled formulations.
Read more →Avalyn Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Avalyn Pharma Inc. has successfully closed its initial public offering, raising $345 million through the sale of 19,166,667 shares at $18.00 each. The offering included the full exercise of an overallotment option by underwriters. The company's stock is now listed on the Nasdaq Global Select Market under the ticker AVLN.
Read more →